Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy

Inclusion Criteria: * Clinical diagnosis of ocular hypertension, primary open angle (including pigment dispersion) glaucoma in both eyes. * IOP considered to be safe, in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period. * Treated with, and in the Investigator's judgment demonstrated an inadequate response to, prostaglandin monotherapy for a minimum of 4 weeks at Visit 1. Last dose of prostaglandin instilled correctly to put patient within the dosing cycle at Visit 1. * At Visit 1, have an IOP of ≥ 20 mmHg in at least one eye and ≤ 35 mmHg in both eyes treated with prostaglandin monotherapy. * Best corrected visual acuity of 1.0 LogMAR or better in each eye. * In any eye not qualifying as a study eye, IOP should be able to be controlled on no pharmacologic therapy or on prostaglandin monotherapy alone. * Willing to sign an informed consent form. * Able to follow instructions and willing and able to attend required study visits. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Known medical history of allergy, hypersensitivity or poor tolerance to any component of AZARGA® that is deemed clinically significant in the opinion of the investigator. * A history of, or at risk for uveitis or cystoid macular edema (CME). * History of ocular herpes simplex. * Corneal dystrophies in either eye. * Concurrent infectious/non infectious conjunctivitis, keratitis or uveitis in either eye (excluding Blepharitis or non-clinically significant conjunctival hyperemia). * Intraocular conventional surgery or laser surgery in study eye(s) less than 3 months prior to Visit 1. * Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. * Progressive retinal or optic nerve disease from any cause apart from glaucoma. * Use of systemic medications known to affect IOP (e.g. oral beta-adrenergic blockers, alpha-agonists and blockers, angiotensin converting enzyme inhibitors and calcium channel blockers), which have not been on a stable course for 7 days prior to Visit 1 or an anticipated change in the dosage during the course of the study. * Use of corticosteroids (oral, topical ocular or nasal) within 30 days of Visit 1 and during the course of the study. * Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker. * History of severe allergic rhinitis. * A condition, which in the opinion of the principal investigator, would interfere with optimal participation in the study, or which would present a special risk to the subject. * Use of any systemic carbonic anhydrase inhibitors (CAI) (e.g. methazolamide \[Neptazane\], acetazolamide \[Diamox\]). * Severely impared renal function. * History of an allergy to sulphonamides. * Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, severe allergic rhinitis or severe chronic obstructive pulmonary disease that would preclude the safe administration of a topical beta-blocker. * Pregnant, lactating, or of childbearing potential and not using a reliable method of birth control. * Any clinically significant, serious, or severe medical condition. * Participation in any other investigational study within 30 days prior to the screening/baseline visit. * Other protocol-defined exclusion criteria may apply.